Excelsior Correspondent
JAMMU, Sept 28: Over the next two to three months, AIIMS Vijaypur will expand to offer comprehensive cancer care, including advanced external radiation treatment, brachytherapy, palliative care services, cancer pain management and cancer surgeries.
“This expansion will eliminate the need for patients to travel outside the State, not only bringing financial relief but also providing psychological comfort to patients and their families by offering high-quality care close to home,” said Prof (Dr) Shakti Kumar Gupta, Executive Director and CEO of AIIMS Jammu.
He said there was a time when patients diagnosed with cancer have been forced to travel outside the State for diagnosis, treatment, and follow-ups. “God has been kind enough to bless me with the opportunity to make a difference for the people of J&K by being instrumental in providing comprehensive cancer care within the State itself,” he added.
Prof Gupta said in his mission to offer world-class cancer treatment, he has ensured that the best and latest equipment will be available at AIIMS Jammu, enabling the medical team to deliver care that meets global standards. He shared that AIIMS Jammu has taken its first significant step beyond outpatient services, successfully administering chemotherapy to its first patient.
He shared the details of a recent case treated at the Department of Radiotherapy Oncology, AIIMS Vijaypur. “The department, under the leadership of Prof (Dr) Shabab Angurana, successfully launched partial oncology services, including chemotherapy, targeted therapies, and immuno-oncology treatments,” he stated.
Prof Gupta said the team, comprising Dr Girija Priya Sharma (Assistant Professor), Dr Anjali Bhola (Assistant Professor), Senior Resident Dr Suridhi Jasrotia, Junior Resident Dr Radhakrishna, and Senior Nursing Officer Arti Sharma, treated their first patient, a relapsed case of ovary carcinoma.
The patient had previously undergone two lines of chemotherapy and treatment with a PARP inhibitor. Presently, she received infusion chemotherapy with Injection Paclitaxel, a conventional chemotherapy drug, and Injection Bevacizumab, a targeted therapy drug. The patient was discharged in stable condition.
Follow our WhatsApp channel
